{"id":986139,"date":"2026-07-29T03:03:31","date_gmt":"2026-07-29T07:03:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/"},"modified":"2026-07-29T03:03:31","modified_gmt":"2026-07-29T07:03:31","slug":"abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/","title":{"rendered":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>RINVOQ<\/i><br \/>\n          <i><br \/>\n            <sup>\u00ae<\/sup><br \/>\n          <\/i><br \/>\n          <i>is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA)<\/i>\n        <\/li>\n<li>\n          <i>Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score \u2264 20) and improvements in eyebrows and eyelashes at week 24<\/i><br \/>\n          <i><br \/>\n            <sup>1<\/sup><br \/>\n          <\/i>\n        <\/li>\n<li>\n          <i>RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">NORTH CHICAGO, Ill.<\/span>, <span class=\"legendSpanClass\">July 29, 2026<\/span> \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ<sup>\u00ae<\/sup>\u00a0(upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).<sup>1<\/sup><\/p>\n<p>&#8220;The European Commission&#8217;s approval of RINVOQ provides a new treatment option for the severe alopecia areata community in the EU with demonstrated scalp regrowth, including complete scalp hair regrowth for some, that can support management of the disease,&#8221; said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. &#8220;This approval provides another option for patients who continue to navigate physical and mental burden associated with severe alopecia areata, often overlooked due to stigma.&#8221;<\/p>\n<p>AA is an unpredictable autoimmune disease that causes a range of hair loss patterns, from sudden, round bald patches on the scalp to complete loss of all body hair, including scalp, face, eyebrows and eyelashes.<sup>2,3<\/sup>\u00a0Despite its immune-mediated nature, AA is often misunderstood as a cosmetic problem despite being associated with a wide-ranging impact on patients&#8217; lives contributing to the physical, psychological, social and economic burden.<sup>4,5 <\/sup>According to a population\u2010based study, patients with alopecia areata face up to 40% higher risk of being diagnosed with new-onset depression and anxiety compared to the general population, and this risk increases in women.<sup>6,7<\/sup><\/p>\n<p>\n        <b>Data Supporting the EC Approval<br \/><\/b>\n      <\/p>\n<p>The\u00a0EC approval of RINVOQ is supported by <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=1452188079&amp;u=https%3A%2F%2Fnews.abbvie.com%2F2025-08-21-AbbVie-Announces-Positive-Topline-Results-from-Second-Phase-3-UP-AA-Trial-Evaluating-Upadacitinib-RINVOQ-R-for-Alopecia-Areata&amp;a=previously+reported+data\" target=\"_blank\" rel=\"nofollow\">previously reported data<\/a>\u00a0from the ongoing Phase 3 UP-AA clinical program (M23-716), which includes two replicate, randomized, placebo-controlled, double-blind studies evaluating the efficacy and safety of RINVOQ in adult and adolescent patients with severe AA.<sup>1<\/sup>\u00a0<\/p>\n<p>Both the 15 mg and 30 mg doses of RINVOQ in each study met the primary endpoint of SALT score \u2264 20 at week 24, with significantly more patients achieving \u2265\u00a080% scalp hair coverage compared with placebo. Key secondary endpoints were also met for both doses in both studies, including complete scalp hair regrowth (SALT = 0) at week 24. The safety profile of both doses of RINVOQ in Period A was generally consistent with that observed in approved indications.<sup>1<\/sup>\u00a0<\/p>\n<p>&#8220;Alopecia areata is a complex condition to treat often due to its unpredictable disease course and prognosis,&#8221; said Thierry Passeron, M.D., Ph.D., professor and chair, Department of Dermatology, Universit\u00e9 C\u00f4te d&#8217;Azur. &#8220;The UP-AA results based on stringent endpoints demonstrated clinically meaningful scalp hair regrowth and improvements in eyebrows and eyelashes in 24 weeks, supporting RINVOQ as an important new treatment option for severe alopecia areata patients in Europe.&#8221;<\/p>\n<p>RINVOQ is also approved in the European Union for the treatment of adults and adolescents with atopic dermatitis, and adults with radiographic axial spondylarthritis, non-radiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn&#8217;s disease, and giant cell arteritis, and adults and adolescents with non-segmental vitiligo.<sup>1<\/sup><\/p>\n<p>\n        <b>About UP-AA Clinical Trials<\/b>\u00a0<br \/>UP-AA M23-716 was conducted as a single protocol that includes two replicate pivotal studies (Study 1 and Study 2) with randomization, investigative sites, data collection, analysis and reporting independent for each study. The Phase 3 randomized, placebo-controlled, double-blind studies evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. In Study 1 and Study 2 Period A, participants are randomized to one of three groups to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo for 24 weeks. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose groups in Period A will continue their same treatment in Period B for 28 weeks. Participants originally randomized to placebo in Period A will either remain on placebo in Period B, or be randomized in one of two groups, based on their SALT score at week 24. In total, Study 1 and Study 2 Periods A and B span 52 weeks. Participants who complete Study 1 or Study 2 can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. The two trials randomized 1,399 participants with severe AA ages 12 to 64 across 248 sites worldwide. More information on this trial can be found at <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=1763228892&amp;u=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;a=www.clinicaltrials.gov\" target=\"_blank\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>\u00a0(NCT06012240).<\/p>\n<p>\n        <b>About RINVOQ<\/b><br \/>\n        <b><br \/>\n          <sup>\u00ae<\/sup><br \/>\n        <\/b>\u00a0<b>(upadacitinib)<br \/><\/b>Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.<sup>1,8<\/sup>\u00a0In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1\/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.<sup>1<\/sup><\/p>\n<p>Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus. The use of upadacitinib in alopecia areata is also under regulatory review by the U.S. FDA.<\/p>\n<p>\n        <b>EU<\/b>\u00a0<b>Indications<\/b>\u00a0<b>and<\/b>\u00a0<b>Important<\/b>\u00a0<b>Safety<\/b>\u00a0<b>Information<\/b>\u00a0<b>about<\/b>\u00a0<b>RINVOQ<\/b><b><sup>\u00ae<\/sup><\/b>\u00a0<b>(upadacitinib)<\/b><b><sup>1 <\/sup><\/b><\/p>\n<p>\n        <b>Indications<\/b>\n      <\/p>\n<p>\n        <u><br \/>\n          <b>Rheumatoid<\/b>\u00a0<b>arthritis<br \/><\/b><\/u>\n      <\/p>\n<p>RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.<\/p>\n<p>\n        <u><br \/>\n          <b>Psoriatic<\/b>\u00a0<\/u><br \/>\n        <b><br \/>\n          <u>arthritis<br \/><\/u><br \/>\n        <\/b>\n      <\/p>\n<p>RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.\u00a0RINVOQ\u00a0may\u00a0be\u00a0used\u00a0as monotherapy or in combination with methotrexate.<\/p>\n<p>\n        <u><br \/>\n          <b>Axial<\/b>\u00a0<b>spondyloarthritis<\/b><\/u>\n      <\/p>\n<p>\n        <b><br \/>\n          <i>Non-radiographic<\/i><br \/>\n        <\/b>\u00a0<b><i>axial<\/i><\/b>\u00a0<b><i>spondyloarthritis<\/i><\/b>\u00a0<b><i>(nr-<\/i><\/b><b><i>axSpA)<\/i><\/b><\/p>\n<p>RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive\u00a0protein\u00a0(CRP)\u00a0and\/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).<\/p>\n<p>\n        <b><br \/>\n          <i>Ankylosing<\/i><br \/>\n        <\/b>\u00a0<b><i>spondylitis<\/i><\/b>\u00a0<b><i>(AS,<\/i><\/b>\u00a0<b><i>radiographic<\/i><\/b>\u00a0<b><i>axial<\/i><\/b>\u00a0<b><i>spondyloarthritis)<\/i><\/b><\/p>\n<p>RINVOQ\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0active\u00a0ankylosing\u00a0spondylitis\u00a0in\u00a0adult\u00a0patients\u00a0who\u00a0have responded inadequately to conventional therapy.<\/p>\n<p>\n        <u><br \/>\n          <b>Giant<\/b>\u00a0<b>cell<\/b><b> arteritis<\/b><\/u>\n      <\/p>\n<p>RINVOQ\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0giant\u00a0cell\u00a0arteritis\u00a0(GCA)\u00a0in\u00a0adult\u00a0patients.<\/p>\n<p>\n        <u><br \/>\n          <b>Atopic<\/b>\u00a0<b>dermatitis<\/b><\/u>\n      <\/p>\n<p>RINVOQ\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0moderate\u00a0to severe\u00a0atopic\u00a0dermatitis\u00a0(AD)\u00a0in\u00a0adults\u00a0and adolescents 12 years and older who are candidates for systemic therapy.<\/p>\n<p>\n        <b><br \/>\n          <u>Alopecia areata<br \/><\/u><br \/>\n        <\/b>\n      <\/p>\n<p>RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.<\/p>\n<p>\n        <b><br \/>\n          <u>Vitiligo<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.<\/p>\n<p>\n        <u><br \/>\n          <b>Ulcerative<\/b>\u00a0<b>colitis<\/b><\/u>\n      <\/p>\n<p>RINVOQ\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0adult\u00a0patients\u00a0with\u00a0moderately\u00a0to\u00a0severely\u00a0active\u00a0ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.<\/p>\n<p>\n        <u><br \/>\n          <b>Crohn&#8217;s<\/b>\u00a0<b>disease<\/b><\/u>\n      <\/p>\n<p>RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn&#8217;s disease\u00a0who\u00a0have\u00a0had\u00a0an\u00a0inadequate\u00a0response,\u00a0lost\u00a0response\u00a0or\u00a0were\u00a0intolerant\u00a0to\u00a0either\u00a0conventional therapy or a biologic agent.<\/p>\n<p>\n        <b>Important<\/b>\u00a0<b>Safety<\/b><b> Information<\/b><\/p>\n<p>\n        <b>Contraindications<br \/><\/b>RINVOQ\u00a0is\u00a0contraindicated\u00a0in\u00a0patients\u00a0hypersensitive\u00a0to the\u00a0active\u00a0substance\u00a0or\u00a0to any\u00a0of\u00a0the\u00a0excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.<\/p>\n<p>\n        <b>Special<\/b>\u00a0<b>warnings<\/b>\u00a0<b>and<\/b>\u00a0<b>precautions<\/b>\u00a0<b>for<\/b><b> use<br \/><\/b>RINVOQ\u00a0should\u00a0only\u00a0be\u00a0used\u00a0if\u00a0no\u00a0suitable\u00a0treatment\u00a0alternatives\u00a0are\u00a0available\u00a0in\u00a0patients:<\/p>\n<ul type=\"disc\">\n<li>65\u00a0years\u00a0of\u00a0age\u00a0and\u00a0older;<\/li>\n<li>patients\u00a0with\u00a0history\u00a0of\u00a0atherosclerotic\u00a0cardiovascular (CV)\u00a0disease\u00a0or\u00a0other\u00a0CV\u00a0risk\u00a0factors\u00a0(such\u00a0as current or past long-time smokers);<\/li>\n<li>patients\u00a0with\u00a0malignancy\u00a0risk\u00a0factors\u00a0(e.g.\u00a0current\u00a0malignancy\u00a0or\u00a0history\u00a0of\u00a0malignancy)<\/li>\n<\/ul>\n<p>\n        <u>Use\u00a0in\u00a0patients\u00a065\u00a0years\u00a0of\u00a0age\u00a0and\u00a0older<br \/><\/u>Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients \u226565 years\u00a0of age, as observed\u00a0in a large\u00a0randomised\u00a0study\u00a0of\u00a0tofacitinib\u00a0(another Janus\u00a0Kinase (JAK) inhibitor),\u00a0RINVOQ\u00a0should\u00a0only be used in\u00a0these\u00a0patients if no suitable treatment\u00a0alternatives are available. In patients \u226565 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg\u00a0once\u00a0daily.\u00a0Consequently,\u00a0the\u00a0recommended\u00a0dose\u00a0for\u00a0long-term\u00a0use\u00a0in\u00a0this\u00a0patient\u00a0population\u00a0is\u00a015 mg once daily.<\/p>\n<p>\n        <u>Immunosuppressive\u00a0medicinal\u00a0products<\/u><br \/>\n        <br \/>Use\u00a0in\u00a0combination\u00a0with\u00a0other\u00a0potent\u00a0immunosuppressants\u00a0is\u00a0not\u00a0recommended.<\/p>\n<p>\n        <u>Serious\u00a0infections<\/u><br \/>\n        <br \/>Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with\u00a0RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral\/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients \u226565 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.<\/p>\n<p>\n        <i>Tuberculosis<br \/><\/i>Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with\u00a0active\u00a0TB.\u00a0Anti-TB\u00a0therapy\u00a0may\u00a0be\u00a0appropriate\u00a0for\u00a0select\u00a0patients\u00a0in\u00a0consultation\u00a0with\u00a0a\u00a0physician with expertise in\u00a0the\u00a0treatment\u00a0of\u00a0TB.\u00a0Patients should\u00a0be monitored for\u00a0the development\u00a0of signs\u00a0and symptoms of TB.<\/p>\n<p>\n        <u>Viral<\/u><br \/>\n        <u> reactivation<br \/><\/u>Viral\u00a0reactivation,\u00a0including\u00a0cases\u00a0of\u00a0herpes\u00a0zoster,\u00a0was\u00a0reported\u00a0in\u00a0clinical\u00a0studies.\u00a0The\u00a0risk\u00a0of\u00a0herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ\u00a0if\u00a0the\u00a0patient\u00a0develops\u00a0herpes\u00a0zoster until\u00a0the\u00a0episode\u00a0resolves.\u00a0Screening\u00a0for\u00a0viral\u00a0hepatitis\u00a0and monitoring for reactivation\u00a0should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.<\/p>\n<p>\n        <u>Vaccination<br \/><\/u>The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended\u00a0that\u00a0patients\u00a0be\u00a0brought\u00a0up\u00a0to\u00a0date\u00a0with\u00a0all\u00a0immunizations,\u00a0including\u00a0prophylactic\u00a0zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.<\/p>\n<p>\n        <u>Malignancy<br \/><\/u>Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients \u226550 years of age with \u22651 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour\u00a0necrosis\u00a0factor\u00a0(TNF)\u00a0inhibitors.\u00a0A\u00a0higher\u00a0rate\u00a0of\u00a0malignancies,\u00a0including\u00a0NMSC,\u00a0was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients \u226565 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.<\/p>\n<p>\n        <u>Hematological\u00a0abnormalities<\/u><br \/>\n        <br \/>Treatment\u00a0should\u00a0not\u00a0be\u00a0initiated,\u00a0or\u00a0should\u00a0be\u00a0temporarily\u00a0interrupted,\u00a0in\u00a0patients\u00a0with\u00a0hematological abnormalities observed during routine patient management.<\/p>\n<p>\n        <u>Gastrointestinal\u00a0perforations<\/u><br \/>\n        <br \/>Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post-marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal\u00a0perforation\u00a0(e.g.,\u00a0patients\u00a0with\u00a0diverticular\u00a0disease,\u00a0a\u00a0history\u00a0of\u00a0diverticulitis,\u00a0or\u00a0who\u00a0are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn&#8217;s disease are at\u00a0increased\u00a0risk for developing\u00a0intestinal perforation. Patients presenting\u00a0with\u00a0new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.<\/p>\n<p>\n        <u>Major\u00a0adverse\u00a0cardiovascular\u00a0events<\/u><br \/>\n        <br \/>MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients \u226550 years of age with \u22651 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed\u00a0with\u00a0tofacitinib\u00a0compared\u00a0to\u00a0TNF\u00a0inhibitors.\u00a0Therefore,\u00a0in\u00a0patients\u00a0\u226565\u00a0years\u00a0of\u00a0age,\u00a0patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.<\/p>\n<p>\n        <u>Lipids<br \/><\/u>RINVOQ\u00a0treatment\u00a0was\u00a0associated\u00a0with\u00a0dose-dependent\u00a0increases\u00a0in\u00a0lipid\u00a0parameters,\u00a0including\u00a0total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.<\/p>\n<p>\n        <u>Hepatic\u00a0transaminase\u00a0elevations<\/u><br \/>\n        <br \/>Treatment\u00a0with RINVOQ\u00a0was associated with\u00a0an increased incidence of\u00a0liver enzyme elevation. Hepatic transaminases\u00a0must be\u00a0evaluated\u00a0at\u00a0baseline\u00a0and\u00a0thereafter\u00a0according\u00a0to\u00a0routine\u00a0patient\u00a0management. If\u00a0alanine\u00a0transaminase\u00a0(ALT)\u00a0or\u00a0aspartate\u00a0transaminase (AST)\u00a0increases\u00a0are\u00a0observed\u00a0and\u00a0drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.<\/p>\n<p>\n        <u>Venous\u00a0thromboembolism<\/u><br \/>\n        <br \/>Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients \u226550 years of age with \u22651 additional CV risk factor, a dose\u2011dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution.\u00a0Patients\u00a0should\u00a0be\u00a0re-evaluated\u00a0periodically\u00a0to assess\u00a0for\u00a0changes\u00a0in\u00a0VTE\u00a0risk.\u00a0Promptly\u00a0evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.<\/p>\n<p>\n        <u>Retinal\u00a0vein\u00a0occlusion<\/u><br \/>\n        <br \/>Retinal vein occlusion has been reported in\u00a0patients treated with JAK inhibitors, including upadacitinib. Patients\u00a0should\u00a0be\u00a0advised\u00a0to\u00a0promptly\u00a0seek\u00a0medical\u00a0care\u00a0in\u00a0case\u00a0they\u00a0experience\u00a0symptoms\u00a0suggestive of retinal vein occlusion.<\/p>\n<p>\n        <u>Hypersensitivity\u00a0reactions<\/u><br \/>\n        <br \/>Serious\u00a0hypersensitivity\u00a0reactions\u00a0such\u00a0as\u00a0anaphylaxis\u00a0and\u00a0angioedema\u00a0have\u00a0been\u00a0reported\u00a0in\u00a0patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.<\/p>\n<p>\n        <u>Hypoglycemia\u00a0in\u00a0patients\u00a0treated\u00a0for\u00a0diabetes<\/u><br \/>\n        <br \/>There\u00a0have\u00a0been\u00a0reports\u00a0of\u00a0hypoglycemia\u00a0following\u00a0initiation\u00a0of\u00a0JAK\u00a0inhibitors,\u00a0including RINVOQ,\u00a0in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.<\/p>\n<p>\n        <u>Medication\u00a0Residue\u00a0in\u00a0Stool<\/u><br \/>\n        <br \/>Reports\u00a0of\u00a0medication\u00a0residue\u00a0in\u00a0stool\u00a0or\u00a0ostomy\u00a0output\u00a0have\u00a0occurred\u00a0in\u00a0patients\u00a0taking RINVOQ.\u00a0Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to\u00a0contact\u00a0their\u00a0healthcare\u00a0professional\u00a0if\u00a0medication\u00a0residue\u00a0is\u00a0observed\u00a0repeatedly.\u00a0Patients\u00a0should\u00a0be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.<\/p>\n<p>\n        <u>Giant\u00a0Cell\u00a0Arteritis<\/u><br \/>\n        <br \/>RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting\u00a0has\u00a0not\u00a0been\u00a0established. Corticosteroids\u00a0should\u00a0be\u00a0given\u00a0according\u00a0to\u00a0medical\u00a0judgement\u00a0and practice guidelines.<\/p>\n<p>\n        <b>Adverse<\/b>\u00a0<b>reactions<br \/><\/b>The\u00a0most\u00a0commonly\u00a0reported\u00a0adverse\u00a0reactions\u00a0in\u00a0RA,\u00a0PsA,\u00a0and\u00a0axSpA clinical trials (\u22652% of patients in at least one of the indications) with\u00a0RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.<\/p>\n<p>The most commonly reported adverse reactions in AD trials\u00a0(\u22652% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.<\/p>\n<p>The\u00a0most\u00a0commonly\u00a0reported\u00a0adverse reactions\u00a0in\u00a0the\u00a0UC\u00a0and\u00a0CD trials\u00a0(\u22653%\u00a0of\u00a0patients)\u00a0with\u00a0RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.<\/p>\n<p>Overall,\u00a0the\u00a0safety\u00a0profile\u00a0observed\u00a0in\u00a0patients\u00a0with\u00a0GCA\u00a0treated\u00a0with\u00a0RINVOQ\u00a015\u00a0mg\u00a0was\u00a0generally consistent with the known safety profile for RINVOQ.<\/p>\n<p>The\u00a0most\u00a0common\u00a0serious\u00a0adverse\u00a0reactions\u00a0were\u00a0serious\u00a0infections.<\/p>\n<p>The\u00a0safety\u00a0profile\u00a0of\u00a0RINVOQ\u00a0with\u00a0long-term\u00a0treatment\u00a0was\u00a0generally\u00a0similar\u00a0to\u00a0the\u00a0safety\u00a0profile\u00a0during the placebo-controlled period across indications.<\/p>\n<p>\n        <b>This<\/b>\u00a0<b>is<\/b>\u00a0<b>not<\/b>\u00a0<b>a<\/b>\u00a0<b>complete<\/b>\u00a0<b>summary<\/b>\u00a0<b>of<\/b>\u00a0<b>all<\/b>\u00a0<b>safety<\/b>\u00a0<b>information. <\/b><\/p>\n<p>\n        <b>S<\/b><br \/>\n        <b>ee<\/b>\u00a0<b>RINVOQ<\/b>\u00a0<b>full<\/b>\u00a0<b>Summary<\/b>\u00a0<b>of<\/b>\u00a0<b>Product<\/b>\u00a0<b>Characteristics<\/b>\u00a0<b>(SmPC)<\/b>\u00a0<b>at<\/b>\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=2264879543&amp;u=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Frinvoq-epar-product-information_en.pdf&amp;a=www.ema.europa.eu\" target=\"_blank\" rel=\"nofollow\"><b>www.ema.europa.eu<\/b><\/a><\/p>\n<p>\n        <b>Globally,<\/b>\u00a0<b>prescribing<\/b>\u00a0<b>information<\/b>\u00a0<b>varies;<\/b>\u00a0<b>refer<\/b>\u00a0<b>to<\/b>\u00a0<b>the<\/b>\u00a0<b>individual<\/b>\u00a0<b>country<\/b>\u00a0<b>product<\/b>\u00a0<b>label<\/b>\u00a0<b>for<\/b>\u00a0<b>complete <\/b><b>information.<\/b><\/p>\n<p>\n        <b>About AbbVie in Immunology<br \/><\/b>AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline \u2013 spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.<\/p>\n<p>Today, more than 1 million patients worldwide are treated with AbbVie&#8217;s immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=2929343021&amp;u=http%3A%2F%2Fwww.abbvie.com%2Fimmunology&amp;a=www.abbvie.com%2Fimmunology\" target=\"_blank\" rel=\"nofollow\">www.abbvie.com\/immunology<\/a>.<\/p>\n<p>\n        <b>About AbbVie<br \/><\/b>AbbVie&#8217;s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people&#8217;s lives across several key therapeutic areas including immunology, neuroscience and oncology \u2013 and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=377454180&amp;u=http%3A%2F%2Fwww.abbvie.com%2F&amp;a=www.abbvie.com\" target=\"_blank\" rel=\"nofollow\">www.abbvie.com<\/a>. Follow @abbvie on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=2112628788&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&amp;a=LinkedIn%2C\" target=\"_blank\" rel=\"nofollow\">LinkedIn,<\/a>\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=483275350&amp;u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=1089040496&amp;u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&amp;a=Instagram\" target=\"_blank\" rel=\"nofollow\">Instagram<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=527062148&amp;u=https%3A%2F%2Ftwitter.com%2Fabbvie&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0and <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=2923585081&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&amp;a=YouTube.\" target=\"_blank\" rel=\"nofollow\">YouTube.<\/a><\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>\n        <i>Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project&#8221; and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; of AbbVie&#8217;s 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.<\/i>\n      <\/p>\n<p>\n        <u>References<\/u>\n      <\/p>\n<ol type=\"1\">\n<li>RINVOQ. Package insert.\u00a0North\u00a0Chicago, IL: AbbVie Inc.; 2026.<\/li>\n<li>Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. <i>J Am Acad Dermatol<\/i>. 2010;62(2):177-188, quiz 189-190.\u00a0doi:10.1016\/j.jaad.2009.10.032<\/li>\n<li>Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. <i>Nat Rev Dis Primers<\/i>. 2017;3(1):17011.\u00a0doi:10.1038\/nrdp.2017.11<\/li>\n<li>Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. <i>Br J Dermatol<\/i>. 2019;180(6):1377-1389. doi:10.1111\/bjd.17463<\/li>\n<li>Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>Br J Dermatol<\/i>. 2020;182(1):130-137.\u00a0doi:10.1111\/bjd.18008<\/li>\n<li>Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care.\u00a0<i>Br J Dermatol<\/i>. 2022;187(1):73-81. doi:10.1111\/bjd.21055<\/li>\n<li>Marahatta S, Agrawal S, Adhikari BR. Psychological impact of alopecia areata.\u00a0<i>Dermatol Res Pract<\/i>. 2020;2020:8879343. doi:10.1155\/2020\/8879343<\/li>\n<li>Pipeline.\u00a0AbbVie. 2026. Accessed July 27, 2026. <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4741145-1&amp;h=3169354619&amp;u=https%3A%2F%2Fwww.abbvie.com%2Fscience%2Fpipeline.html&amp;a=https%3A%2F%2Fwww.abbvie.com%2Fscience%2Fpipeline.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.abbvie.com\/science\/pipeline.html<\/a><\/li>\n<\/ol>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Global Media:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Mary Byun<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:mary.byun@abbvie.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">mary.byun@abbvie.com<\/a><\/p>\n<p>                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>U.S. Media:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Sarah Kittel<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:sarah.kittel@abbvie.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">sarah.kittel@abbvie.com<\/a>\u00a0\u00a0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investors: <\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Liz Shea<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:liz.shea@abbvie.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">liz.shea@abbvie.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n              \n            <\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n              \n            <\/td>\n<\/tr>\n<\/table><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata-302837179.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata-302837179.html<\/a><\/p>\n<p>SOURCE AbbVie<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG14439&amp;Transmission_Id=202607290300PR_NEWS_USPR_____CG14439&amp;DateId=20260729\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire RINVOQ \u00ae is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score \u2264 20) and improvements in eyebrows and eyelashes at week 24 1 RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24 NORTH CHICAGO, Ill., July 29, 2026 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ\u00ae\u00a0(upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-986139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire RINVOQ \u00ae is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score \u2264 20) and improvements in eyebrows and eyelashes at week 24 1 RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24 NORTH CHICAGO, Ill., July 29, 2026 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ\u00ae\u00a0(upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 &hellip; Continue reading &quot;AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T07:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata\",\"datePublished\":\"2026-07-29T07:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/\"},\"wordCount\":3470,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CG14439&amp;sd=2026-07-29\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/\",\"name\":\"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CG14439&amp;sd=2026-07-29\",\"datePublished\":\"2026-07-29T07:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#primaryimage\",\"url\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CG14439&amp;sd=2026-07-29\",\"contentUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CG14439&amp;sd=2026-07-29\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk","og_description":"PR Newswire RINVOQ \u00ae is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score \u2264 20) and improvements in eyebrows and eyelashes at week 24 1 RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24 NORTH CHICAGO, Ill., July 29, 2026 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ\u00ae\u00a0(upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 &hellip; Continue reading \"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-29T07:03:31+00:00","og_image":[{"url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata","datePublished":"2026-07-29T07:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/"},"wordCount":3470,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/","name":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29","datePublished":"2026-07-29T07:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#primaryimage","url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29","contentUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG14439&amp;sd=2026-07-29"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=986139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=986139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=986139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=986139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}